POXEL FRANCE (PXXLF) Stock Price, News & Analysis

Company Overview

Poxel France (OTCMKTS:PXXLF) is a clinical‐stage biotechnology company dedicated to developing innovative treatments for metabolic diseases. The firm’s core focus lies in the modulation of mitochondrial function and metabolic pathways, with an emphasis on addressing conditions such as type 2 diabetes, nonalcoholic steatohepatitis (NASH) and diabetic kidney disease. Poxel employs a precision medicine approach, leveraging small‐molecule candidates designed to restore cellular bioenergetics and improve insulin sensitivity.

The company’s lead asset, imeglimin, is undergoing regulatory review for type 2 diabetes treatment and has received approval in certain Asian markets under strategic partnerships. In addition to imeglimin, Poxel’s pipeline features PXL770, a direct activator of the AMPK enzyme with potential application in NASH, and PXL065, a deuterated form of pioglitazone engineered for improved safety and efficacy in diabetic kidney disease. These candidates reflect Poxel’s commitment to advancing therapies that address both glycemic control and associated comorbidities.

Founded in 2012, Poxel maintains dual headquarters in Lyon, France, and Boston, Massachusetts, facilitating global clinical development and regulatory interactions. The company is publicly traded on Euronext Paris and is accessible to U.S. investors on the OTC market under the ticker PXXLF. Over the years, Poxel has established collaborations with leading pharmaceutical partners in Europe, North America and Asia to support commercialization and expand its reach in key therapeutic areas.

Under the leadership of Chief Executive Officer Gilles Daher and a management team with deep experience in endocrinology and liver disease research, Poxel continues to advance its strategic objectives. The company’s governance structure emphasizes scientific rigor, regulatory discipline and strategic alliances, positioning Poxel to potentially address unmet medical needs and deliver value through its novel metabolic disease portfolio.

Key Stats

• Today's Range: $0.25 to $0.25
• 50-Day Range: $0.25 to $0.25
• 52-Week Range: $0.25 to $0.25
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXXLF Stock Analysis - Frequently Asked Questions

How have PXXLF shares performed this year?

POXEL FRANCE's stock was trading at $0.25 on January 1st, 2025. Since then, PXXLF stock has increased by 0.0% and is now trading at $0.25.

How do I buy shares of POXEL FRANCE?

Shares of PXXLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PXXLF
• CIK: N/A
• Web: www.poxel.com
• Phone: 33-4-37-37-20-10
• Fax: 043-770-8815
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $710 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.40